Biologically-Adapted, Dose-Escalated Radiotherapy for the Treatment of Ewing Sarcoma, BEAR Trial

This clinical trial evaluates the effect of radiotherapy doses based on tumor size and tumor-specific characteristics (biologically-adapted) in treating patients with Ewing sarcoma. Radiotherapy uses high energy x-rays, particles, or radioactive seeds to kill tumor cells and shrink tumors. Conventional radiotherapy uses minimal imaging support to determine the positioning of radiotherapy. Hypofractionated radiotherapy delivers higher doses of radiotherapy over a shorter period of time and may kill more tumor cells and have fewer side effects. Dose-escalated radiotherapy uses doses that are hig

Trial Details

NCT ID
NCT07188532
Phase
NA
Sponsor
Mayo Clinic
Status
RECRUITING
Cancer Type
Osteosarcoma Sarcoma
Interventions
  • Biospecimen Collection
  • Chemotherapy
  • Computed Tomography
  • Conventional Radiotherapy
  • Definitive Surgical Resection
  • Dose-escalated Radiation Therapy
Locations (sample)
  • Phoenix, Arizona, United States|33.44838,-112.07404
  • Rochester, Minnesota, United States|44.02163,-92.4699

Key Eligibility Criteria

  • Histological confirmation of Ewing sarcoma, including both skeletal and extra-skeletal primary tumors. Patients with "Ewing-like" sarcoma may be el…
  • Patients of age ≥ 2 years are eligible for the study
  • Lansky or Karnofsky performance status ≥ 70
  • Ability to provide written informed consent and complete questionnaire(s) by themselves or with assistance

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Osteosarcoma Sarcoma Trials on Trialify →